Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds_老虎社区_美港股上老虎

Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds

Dow Jones2021-11-22

Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.

The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile "was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose."

BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

130

Jules_Huat
·2021-11-23
Hmmm ok...
回复
2
举报
小小仙女
·2021-11-23
Like
回复
2
举报
小小仙女
·2021-11-23
Tell me your opinion about this news...
回复
2
举报
收起
- MengKeng:
  it is good for little children who can be vaccinated and also people who hold Pfizer shares, haha
  2021-11-23
  回复
  举报
koolgal
·2021-11-23
Pfizer & BioNTech will reap massive profits from vaccines alone since Covid-19 looks like it is here to stay. Share prices of these 2 companies will also rise in tandem! Go Pfizer! Go BioNTech! 🚀🚀🚀🌙🌙🌙
回复
17
举报
收起
- koolgal:
  Thanks
  2021-11-23
  回复
  举报
- 3f585b4d:
  👍
  2021-11-23
  回复
  举报
- koolgal:
  Yes that is true
  2021-11-23
  回复
  举报
查看更多 2 条评论
Dawang
·2021-11-22
Time to protect our young tooo.;) Then travelling can truly take place.
回复
4
举报
收起
- Nez:
  Yes
  2021-11-22
  回复
  举报
MHh
·2021-11-22
As with the adult population, we don’t know the long term safety data. We know that in adults, efficacy lasts only about 6 months. Very disturbing data…
回复
7
举报
hpt
·2021-11-22
Ok
回复
4
举报
Universe宇宙
·2021-11-22
Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.
回复
8
举报
收起
- Universe宇宙回复RandyHall:
  should aim higher, can it make people immune from covid virus, just like the smallpox vaccine that result in immunity from smallpox with 1 jab.
  2021-11-22
  回复
  举报
- Universe宇宙:
  is the study global or on certain countries?
  2021-11-22
  回复
  举报
- Universe宇宙:
  does it result in immunity against the covid virus?
  2021-11-22
  回复
  举报
查看更多 2 条评论
Grit100
·2021-11-22
Ok.
回复
7
举报
FALCON
·2021-11-22
Like
回复
6
举报
Ermmmmmm
·2021-11-22
Push for more revenue
回复
7
举报
DZL
·2021-11-22
yet another revenue wave boost for Pfizer, BioNTech
回复
7
举报
收起
- Investcub:
  Agreed, up up and away !
  2021-11-22
  回复
  举报
- SmallYang:
  agree
  2021-11-22
  回复
  举报
ThunderPat
·2021-11-22
👍
回复
4
举报
HeroSmurf
·2021-11-22
Moderna??
回复
3
举报
Kel9670ong
·2021-11-22
Nice.. Finally the teenage can get some protection against covid
回复
2
举报
supergrowth
·2021-11-22
Nice
回复
3
举报
收起
- Michaeltql:
  Agree
  2021-11-22
  回复
  举报
BoonHuat
·2021-11-22
Nice.
回复
5
举报
收起
- GlitterD:
  Nice
  2021-11-22
  回复
  举报
WaitLongLong
·2021-11-22
👍
回复
5
举报
收起
- supergrowth:
  like
  2021-11-22
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2185787906?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-22 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2185787906","market":"us","top_or_hot":-1,"title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","media":"Dow Jones","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n2021-11-22 20:12 北京时间&nbsp;&nbsp;&nbsp;<strong>Dow Jones</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":null,"article_id":"2185787906","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","pubTimestamp":1637583120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"translate_title":"辉瑞和生物技术公司表示，后续的第三阶段研究表明，疫苗对12至15岁的人是安全的","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":0.9,"PFE":0.9},"content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":875881634,"gmtCreate":1637632189481,"gmtModify":1637632189632,"author":{"id":"4087701041209060","authorId":"4087701041209060","name":"Jules_Huat","avatar":"https://static.tigerbbs.com/fe9434f2d74a5a6650dea45210ebefef","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4087701041209060","authorIdStr":"4087701041209060"},"htmlText":"Hmmm ok...","listText":"Hmmm ok...","text":"Hmmm ok...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875881634","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875345588,"gmtCreate":1637620659278,"gmtModify":1637620659373,"author":{"id":"3582066919253361","authorId":"3582066919253361","name":"小小仙女","avatar":"https://static.tigerbbs.com/0d27c4a861152e8230ec63a6b19da079","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3582066919253361","authorIdStr":"3582066919253361"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875345588","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875345298,"gmtCreate":1637620653114,"gmtModify":1637620653204,"author":{"id":"3582066919253361","authorId":"3582066919253361","name":"小小仙女","avatar":"https://static.tigerbbs.com/0d27c4a861152e8230ec63a6b19da079","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3582066919253361","authorIdStr":"3582066919253361"},"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875345298","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6684587,"gmtCreate":1637623628084,"gmtModify":1637623628175,"authorId":3582668988155006,"author":{"id":3582668988155006,"idStr":"3582668988155006","authorId":3582668988155006,"name":"MengKeng","avatar":"https://static.tigerbbs.com/daf999525f61ba41d3c13b0ed728eb77","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875345298,"type":1,"supId":0,"prevId":0,"content":"it is good for little children who can be vaccinated and also people who hold Pfizer shares, <u>haha</u>","text":"it is good for little children who can be vaccinated and also people who hold Pfizer shares, <u>haha</u>","html":"it is good for little children who can be vaccinated and also people who hold Pfizer shares, <u>haha</u>"}],"langContent":"CN"},{"id":875351653,"gmtCreate":1637617999589,"gmtModify":1637620331525,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"htmlText":"Pfizer &amp; BioNTech will reap massive profits from vaccines alone since Covid-19 looks like it is here to stay.&nbsp; Share prices of these 2 companies will also rise in tandem!&nbsp; Go Pfizer! Go BioNTech! 🚀🚀🚀🌙🌙🌙","listText":"Pfizer &amp; BioNTech will reap massive profits from vaccines alone since Covid-19 looks like it is here to stay.&nbsp; Share prices of these 2 companies will also rise in tandem!&nbsp; Go Pfizer! Go BioNTech! 🚀🚀🚀🌙🌙🌙","text":"Pfizer & BioNTech will reap massive profits from vaccines alone since Covid-19 looks like it is here to stay. Share prices of these 2 companies will also rise in tandem! Go Pfizer! Go BioNTech! 🚀🚀🚀🌙🌙🌙","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":17,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/875351653","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6690071,"gmtCreate":1637644697971,"gmtModify":1637644697971,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875351653,"type":1,"supId":6689945,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"},{"id":6689945,"gmtCreate":1637643940800,"gmtModify":1637643940836,"authorId":4094345516143680,"author":{"id":4094345516143680,"idStr":"4094345516143680","authorId":4094345516143680,"name":"3f585b4d","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875351653,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"},{"id":6687437,"gmtCreate":1637631207682,"gmtModify":1637631207682,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875351653,"type":1,"supId":6686990,"prevId":0,"content":"Yes that is true","text":"Yes that is true","html":"Yes that is true"},{"id":6683987,"gmtCreate":1637621654110,"gmtModify":1637621654110,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875351653,"type":1,"supId":6683823,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"},{"id":6683984,"gmtCreate":1637621646743,"gmtModify":1637621646743,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875351653,"type":1,"supId":6683899,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"}],"langContent":"CN"},{"id":875043230,"gmtCreate":1637591927817,"gmtModify":1637591928448,"author":{"id":"3579482809178950","authorId":"3579482809178950","name":"Dawang","avatar":"https://static.tigerbbs.com/d0f01f2346125f600328ffd48beb3a4c","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3579482809178950","authorIdStr":"3579482809178950"},"htmlText":"Time to protect our young tooo.;) Then travelling can truly take place.","listText":"Time to protect our young tooo.;) Then travelling can truly take place.","text":"Time to protect our young tooo.;) Then travelling can truly take place.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875043230","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6680527,"gmtCreate":1637592091440,"gmtModify":1637592091544,"authorId":3577664011514694,"author":{"id":3577664011514694,"idStr":"3577664011514694","authorId":3577664011514694,"name":"Nez","avatar":"https://static.tigerbbs.com/b32d6842fa474340581d116936497abb","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875043230,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"CN"},{"id":875062126,"gmtCreate":1637589742037,"gmtModify":1637589743060,"author":{"id":"4091758936365950","authorId":"4091758936365950","name":"MHh","avatar":"https://static.tigerbbs.com/54b2feced9ef5dcc9e95997d1f4db280","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"4091758936365950","authorIdStr":"4091758936365950"},"htmlText":"As with the adult population, we don’t know the long term safety data. We know that in adults, efficacy lasts only about 6 months. Very disturbing data…","listText":"As with the adult population, we don’t know the long term safety data. We know that in adults, efficacy lasts only about 6 months. Very disturbing data…","text":"As with the adult population, we don’t know the long term safety data. We know that in adults, efficacy lasts only about 6 months. Very disturbing data…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875062126","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875014736,"gmtCreate":1637587656325,"gmtModify":1637587656465,"author":{"id":"3579759306103275","authorId":"3579759306103275","name":"hpt","avatar":"https://static.tigerbbs.com/986ef7c951112f7be64cfd5d6c1672c5","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3579759306103275","authorIdStr":"3579759306103275"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875014736","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875012933,"gmtCreate":1637587348565,"gmtModify":1637592284634,"author":{"id":"3585001294737518","authorId":"3585001294737518","name":"Universe宇宙","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3585001294737518","authorIdStr":"3585001294737518"},"htmlText":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.","listText":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.","text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":8,"commentSize":18,"repostSize":0,"link":"https://laohu8.com/post/875012933","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6680764,"gmtCreate":1637592803130,"gmtModify":1637602182523,"authorId":3585001294737518,"author":{"id":3585001294737518,"idStr":"3585001294737518","authorId":3585001294737518,"name":"Universe宇宙","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":9000000000000176,"repliedAuthor":{"id":9000000000000176,"idStr":"9000000000000176","authorId":9000000000000176,"name":"RandyHall","avatar":"https://static.tigerbbs.com/9a2c539bd7eff494d3755975b44673ef","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":875012933,"type":1,"supId":6680473,"prevId":6680658,"content":"should aim higher, can it make people immune from covid virus, just like the smallpox vaccine that result in immunity from smallpox with 1 jab.","text":"should aim higher, can it make people immune from covid virus, just like the smallpox vaccine that result in immunity from smallpox with 1 jab.","html":"should aim higher, can it make people immune from covid virus, just like the smallpox vaccine that result in immunity from smallpox with 1 jab."},{"id":6680605,"gmtCreate":1637592334433,"gmtModify":1637602181515,"authorId":3585001294737518,"author":{"id":3585001294737518,"idStr":"3585001294737518","authorId":3585001294737518,"name":"Universe宇宙","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875012933,"type":1,"supId":0,"prevId":0,"content":"is the study global or on certain countries?","text":"is the study global or on certain countries?","html":"is the study global or on certain countries?"},{"id":6680534,"gmtCreate":1637592109333,"gmtModify":1637602181157,"authorId":3585001294737518,"author":{"id":3585001294737518,"idStr":"3585001294737518","authorId":3585001294737518,"name":"Universe宇宙","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875012933,"type":1,"supId":0,"prevId":0,"content":"does it result in immunity against the covid virus?","text":"does it result in immunity against the covid virus?","html":"does it result in immunity against the covid virus?"},{"id":6680854,"gmtCreate":1637593056985,"gmtModify":1637593057018,"authorId":3585001294737518,"author":{"id":3585001294737518,"idStr":"3585001294737518","authorId":3585001294737518,"name":"Universe宇宙","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875012933,"type":1,"supId":0,"prevId":0,"content":"does poor countries got these vaccines?","text":"does poor countries got these vaccines?","html":"does poor countries got these vaccines?"},{"id":6680818,"gmtCreate":1637592955776,"gmtModify":1637592955879,"authorId":3585001294737518,"author":{"id":3585001294737518,"idStr":"3585001294737518","authorId":3585001294737518,"name":"Universe宇宙","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875012933,"type":1,"supId":6680661,"prevId":0,"content":"maybe USD 150 by the end of Q1 2022?","text":"maybe USD 150 by the end of Q1 2022?","html":"maybe USD 150 by the end of Q1 2022?"}],"langContent":"CN"},{"id":875098049,"gmtCreate":1637584564017,"gmtModify":1637584564137,"author":{"id":"3581502897038686","authorId":"3581502897038686","name":"Grit100","avatar":"https://static.tigerbbs.com/c3c65cb20cfcce91cc07fddb27bc3ccd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581502897038686","authorIdStr":"3581502897038686"},"htmlText":"Ok.","listText":"Ok.","text":"Ok.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875098049","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875091400,"gmtCreate":1637584556056,"gmtModify":1637584556174,"author":{"id":"3584817540991212","authorId":"3584817540991212","name":"FALCON","avatar":"https://static.tigerbbs.com/c0d98873fea539ae720f8695900f4238","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3584817540991212","authorIdStr":"3584817540991212"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875091400","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875091597,"gmtCreate":1637584540604,"gmtModify":1637584556134,"author":{"id":"4087557783698070","authorId":"4087557783698070","name":"Ermmmmmm","avatar":"https://static.tigerbbs.com/b89bbeb73fe9212f0b5efc7185ae8a51","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087557783698070","authorIdStr":"4087557783698070"},"htmlText":"Push for more revenue&nbsp;","listText":"Push for more revenue&nbsp;","text":"Push for more revenue","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875091597","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875093468,"gmtCreate":1637584446342,"gmtModify":1637584446547,"author":{"id":"3582006183410147","authorId":"3582006183410147","name":"DZL","avatar":"https://static.tigerbbs.com/640ac3ae648fded99146300a53c24a5b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3582006183410147","authorIdStr":"3582006183410147"},"htmlText":"yet another revenue wave&nbsp;boost for Pfizer, BioNTech&nbsp;","listText":"yet another revenue wave&nbsp;boost for Pfizer, BioNTech&nbsp;","text":"yet another revenue wave boost for Pfizer, BioNTech","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/875093468","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6679801,"gmtCreate":1637588880130,"gmtModify":1637588880160,"authorId":3584582153384625,"author":{"id":3584582153384625,"idStr":"3584582153384625","authorId":3584582153384625,"name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875093468,"type":1,"supId":0,"prevId":0,"content":"Agreed, up up and away !","text":"Agreed, up up and away !","html":"Agreed, up up and away !"},{"id":6679142,"gmtCreate":1637584759447,"gmtModify":1637584759475,"authorId":4088082610944870,"author":{"id":4088082610944870,"idStr":"4088082610944870","authorId":4088082610944870,"name":"SmallYang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875093468,"type":1,"supId":0,"prevId":0,"content":"<u>agree</u>","text":"<u>agree</u>","html":"<u>agree</u>"}],"langContent":"CN"},{"id":875099451,"gmtCreate":1637584344681,"gmtModify":1637584344816,"author":{"id":"4094290551126310","authorId":"4094290551126310","name":"ThunderPat","avatar":"https://static.tigerbbs.com/27ae321aaa87241102a9ecad3a243f74","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4094290551126310","authorIdStr":"4094290551126310"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875099451","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875099500,"gmtCreate":1637584342031,"gmtModify":1637584342148,"author":{"id":"3585642689958579","authorId":"3585642689958579","name":"HeroSmurf","avatar":"https://static.tigerbbs.com/6015b234d96461c6ef8db8d919ac3473","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3585642689958579","authorIdStr":"3585642689958579"},"htmlText":"Moderna??","listText":"Moderna??","text":"Moderna??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875099500","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875090131,"gmtCreate":1637584188204,"gmtModify":1637588606957,"author":{"id":"3578468158955348","authorId":"3578468158955348","name":"Kel9670ong","avatar":"https://static.tigerbbs.com/bd86c42e207fbd94e7f8877a29457d71","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578468158955348","authorIdStr":"3578468158955348"},"htmlText":"Nice.. Finally the teenage can get some protection against covid","listText":"Nice.. Finally the teenage can get some protection against covid","text":"Nice.. Finally the teenage can get some protection against covid","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875090131","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875005004,"gmtCreate":1637583869887,"gmtModify":1637583869992,"author":{"id":"3581854803062408","authorId":"3581854803062408","name":"supergrowth","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581854803062408","authorIdStr":"3581854803062408"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875005004","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6679063,"gmtCreate":1637584158214,"gmtModify":1637584158243,"authorId":3581511363085578,"author":{"id":3581511363085578,"idStr":"3581511363085578","authorId":3581511363085578,"name":"Michaeltql","avatar":"https://static.tigerbbs.com/5702cc9f095edfd93423e103aff18cfe","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875005004,"type":1,"supId":0,"prevId":0,"content":"Agree","text":"Agree","html":"Agree"}],"langContent":"CN"},{"id":875008918,"gmtCreate":1637583519244,"gmtModify":1637583519387,"author":{"id":"3574549633778650","authorId":"3574549633778650","name":"BoonHuat","avatar":"https://static.tigerbbs.com/f64154b666040668c472fc3731becde7","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3574549633778650","authorIdStr":"3574549633778650"},"htmlText":"Nice.","listText":"Nice.","text":"Nice.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875008918","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6678994,"gmtCreate":1637583616703,"gmtModify":1637583616746,"authorId":3579840343067603,"author":{"id":3579840343067603,"idStr":"3579840343067603","authorId":3579840343067603,"name":"GlitterD","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875008918,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"CN"},{"id":875001501,"gmtCreate":1637583471564,"gmtModify":1637583471741,"author":{"id":"3575536811342573","authorId":"3575536811342573","name":"WaitLongLong","avatar":"https://static.tigerbbs.com/accd08583e64e6324f2a953f232561ef","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3575536811342573","authorIdStr":"3575536811342573"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875001501","repostId":2185787906,"repostType":4,"repost":{"id":"2185787906","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637583120,"share":"https://www.laohu8.com/m/news/2185787906?lang=&edition=full","pubTime":"2021-11-22 20:12","market":"us","language":"en","title":"Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds","url":"https://stock-news.laohu8.com/highlight/detail?id=2185787906","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analy","content":"<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech say follow-on Phase III study shows vaccine safe for 12- to 15-year-olds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-22 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.</p>\n<p>The follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"</p>\n<p>BioNTech shares rose 2% and Pfizer added 1% in pre-market trades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185787906","content_text":"Pfizer Inc. $(PFE)$ and BioNTech SE (BNTX) said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19.\nThe follow-up test measured seven days through four-plus months after the second dose. The companies said the adverse event profile \"was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least six months of safety follow-up after the second dose.\"\nBioNTech shares rose 2% and Pfizer added 1% in pre-market trades.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6679023,"gmtCreate":1637583881777,"gmtModify":1637583881873,"authorId":3581854803062408,"author":{"id":3581854803062408,"idStr":"3581854803062408","authorId":3581854803062408,"name":"supergrowth","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875001501,"type":1,"supId":0,"prevId":0,"content":"like","text":"like","html":"like"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":130,"commentSize":18,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}